Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.
Two anti-TROP2 ADCs join cell therapies and Teva’s anti-PD-1 in first-in-human studies.
After being burned by Point, Lilly is taking a slower approach with Radionetics.
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
The EU recommendation for odronextamab comes after a US rejection in March.
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
